Patent intelligence · US
US 11098126
Anti-MET antibodies and uses thereof
Anti-MET antibodies and uses thereof
Patent details — US 11098126
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 24, 2021
- Expiration
- Aug 19, 2041
- Applicant
- AGOMAB THERAPEUTICS BVBA
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/00
Quick answer
US 11098126 (Anti-MET antibodies and uses thereof) is held by AGOMAB THERAPEUTICS BVBA. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AGOMAB THERAPEUTICS BVBA
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/00, A61P1/04, A61P1/16
More from AGOMAB THERAPEUTICS BVBA
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11098126?
US 11098126 (Anti-MET antibodies and uses thereof) is held by AGOMAB THERAPEUTICS BVBA. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11098126?
AGOMAB THERAPEUTICS BVBA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11098126 expire?
Our index shows an expiration date of Aug 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.